A process for the manufacturing of alkanesulfonic acid by reaction of an alkane with an anhydride in the presence of sulfuric acid and a starter at ambient temperature or higher and under pressure.

The present invention provides an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin having a polarity that increases by an action of an acid, and (B) a compound that generates an acid upon irradiation with actinic rays or radiation, represented by a specific general formula, is which the resin (A) includes a repeating unit represented by a specific general formula; and an actinic ray-sensitive or radiation-sensitive film formed of the actinic ray-sensitive or radiation-sensitive resin composition, a pattern forming method, and a method for manufacturing an electronic device.

The present invention provides an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin having a polarity that increases by an action of an acid, and (B) a compound that generates an acid upon irradiation with actinic rays or radiation, represented by a specific general formula, is which the resin (A) includes a repeating unit represented by a specific general formula; and an actinic ray-sensitive or radiation-sensitive film formed of the actinic ray-sensitive or radiation-sensitive resin composition, a pattern forming method, and a method for manufacturing an electronic device.

A method for recovering a distillable, anhydrous methane-sulfonic acid (MSA) liquid phase from an anhydrous 2-phase gas-liquid mixture wherein the anhydrous 2-phase gas-liquid mixture is generated by sulfonating methane (CH.sub.4) with sulfur trioxide (SO.sub.3) in an MSA-forming reactor, or reactor system, according to a radical chain reaction wherein the method comprises (i) separating the gas phase from the liquid phase, (ii) passing the separated liquid phase into a stripping column, and (iii) recovering the stripped anhydrous liquid phase.

A method for recovering a distillable, anhydrous methane-sulfonic acid (MSA) liquid phase from an anhydrous 2-phase gas-liquid mixture wherein the anhydrous 2-phase gas-liquid mixture is generated by sulfonating methane (CH.sub.4) with sulfur trioxide (SO.sub.3) in an MSA-forming reactor, or reactor system, according to a radical chain reaction wherein the method comprises (i) separating the gas phase from the liquid phase, (ii) passing the separated liquid phase into a stripping column, and (iii) recovering the stripped anhydrous liquid phase.

The present invention relates to a process for preparing haloalkanesulfonic acids from sulfur trioxide and a haloalkane, particularly to a process for preparing trifluoromethane sulfonic acid from sulfur trioxide and trifluoromethane.

The present invention relates to a process for preparing haloalkanesulfonic acids from sulfur trioxide and a haloalkane, particularly to a process for preparing trifluoromethane sulfonic acid from sulfur trioxide and trifluoromethane.

Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.

##STR00001##

Disclosed in the present invention are a crystal form of monomethanesulfonate of a deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound as represented by formula I, and a preparation method therefor. The crystal form is highly stable, can be used for treatment or prevention of diseases or conditions by means of epidermal growth factor receptors (EGFRs) in some mutation forms, can effectively inhibit the growth of a variety of tumor cells, and have an inhibiting effect on other proteases of EGFR and Her families, and thus can be used for preparing antitumor drugs.

Disclosed in the present invention are a crystal form of monomethanesulfonate of a deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound as represented by formula I, and a preparation method therefor. The crystal form is highly stable, can be used for treatment or prevention of diseases or conditions by means of epidermal growth factor receptors (EGFRs) in some mutation forms, can effectively inhibit the growth of a variety of tumor cells, and have an inhibiting effect on other proteases of EGFR and Her families, and thus can be used for preparing antitumor drugs.